Resveratrol inhibition of herpes simplex virus replication

Antiviral Research

Volumn 43, Issue 3, 1999, Pages 145-155

  Docherty, John J ^a   Fu, Ming Ming H ^a   Stiffler, Brian S ^a   Limperos, Richard J ^a   Pokabla, Christopher M ^a   Delucia, Angelo L ^a  

^a Northeast Ohio Medical University   (United States)

Author keywords

Cell infection; Herpes; Resveratrol; Virus

Indexed keywords

PHYTOALEXIN; PICEATANOL; RESVERATROL; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CYCLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VERO CELL; VIRUS CELL INTERACTION; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 0032851133     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00042-X     Document Type: Article

References (39)

1. Bates P.A., DeLuca N.A. The polyserine tract of herpes simplex virus ICP-4 is required for normal viral gene expression and growth in murine trigeminal ganglia. J. Virol. 72:1998;7115-7124.
2. Cobo M. Ocular herpes simplex infections. Mayo Clin. Proc. 63:1988;1154-1156.
3. Coen D.M., Schaffer P.A. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc. Natl. Acad. Sci. U.S.A. 77:1980;2265-2269.
4. Corey L., Adams H., Brown A., Holmes K. Genital herpes simplex virus infections: clinical manifestations, course and complications. Ann. Interm. Med. 98:1983;958-972.
5. Crumpacker C.S., Chartrand P., Subak-Sharp J.H., Wilkie N.M. Resistance of herpes simplex virus to acycloguanosine-genetic and physical analysis. Virology. 105:1980;171-184.
6. Crumpacker C.S., Schnipper L.E., Marlow S.I., Kowalsky P.N., Hershey B.J., Levin M.J. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N. Eng. J. Med. 306:1982;343-346.
7. DeLuca N.A., Schaffer P.A. Activation of immediate early, early, and late promotors by temperature-sensitive and wild-type forms of herpes simplex virus type 1 protein ICP-4. Mol. Cell. Biol. 5:1985;1997-2008.
8. Dixon R.A.F., Schaffer P.A. Fine structure mapping and functional analysis of temperature-sensitive mutants in the gene encoding the herpes simplex virus type 1 immediate early protein VP175. J. Virol. 36:1980;189-203.
9. Docherty J.J., Goldberg R.J., Rapp F. Differential effect of 7, 12-dimethylbenz (a) anthracene on infectivitiy of herpes simplex virus type 2. Proc. Soc. Exp. Biol. Med. 136:1971;328-333.
10. Elion G.B. Mechanism of action and selectivity of acyclovir. Am. J. Med. 1:1996;7.
11. Fauconneau B., Waffo-Teguo P., Huguet F., Barrier L., Decendit A., Merillon J.M. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci. 61:1997;2103-2110.
12. Fontecave M., Lepoivre M., Elleingand E., Gerez C., Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 421:1998;277-279.
13. Frankel E.N., Waterhouse A.L., Kinsella J.E. Inhibition of human LDL oxidation by resveratrol. Lancet. 341:1993;1103-1104.
14. Gilman S.C., Docherty J.J., Clarke A., Rawls W.E. Reaction patterns of herpes simplex virus type 1 and type 2 proteins with sera of patients with uterine cervical carcinoma and matched controls. Cancer Res. 40:1980;4640-4647.
15. Goldberg D.M., Hahn S.E., Parkes J.G. Beyond alcohol:beverage consumption and cardiovascular mortality. Clin. Chim. Acta. 237:1995;155-187.
16. Goldstein D.J., Weller S.K. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase:characterization of an ICP6 deletion mutant. Virology. 166:1988;41-51.
17. Hain R., Bieseler B., Kindl H., Schroeder G., Stoecker R. Expression of a stilbene synthase gene in Nicotians-tobacum results in synthesis of the phytoalexin resveratrol. Plant Mol. Biol. 15:1990;325-336.
18. Idowa A.D., Fraser-Smith E.B., Paffenberger K.L., Herman R.C. Deletion of herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vitro. Antiviral Res. 17:1992;145-156.
19. Jacobsen J.G., Leib D.A., Goldstein D.J., Bogard C.L., Schaffer P.A., Weller S.K., Coen D.M. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice for replication in mouse cells. Virology. 173:1989;276-283.
20. Jang M., Cai L., Udeani G.O. et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:1997;218-220.
21. O'Hare P. The virion transactivator of herpes simplex virus. Semin. Virol. 4:1993;145-156.
22. Oliver N.M., Collins P., Van der Meer J., Vant Wout J.W. Biological and biochemical characterization of clinical isolates of herpes simplex virus type 2 resistant to acyclovir. Antimicrob. Agents Chemother. 33:1989;635-640.
23. Pace-Asciak C.R., Hahn S., Diamandis E.P., Soleas G., Goldberg D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta. 235:1995;207-219.
24. Pace-Asciak C.R., Rounova O., Hahn S.E., Diamandis E.P., Goldberg D.M. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin. Chim. Acta. 246:1996;163-182.
25. 2 phase transition. Biochem. Biophys. Res. Comm. 250:1998;53-58.
26. Sawtell N.M. The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently-infected neurons in the ganglia. J. Virol. 72:1998;6888-6892.
27. Schang L.M., Phillips J., Schaffer P.A. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J. Virol. 72:1998;5626-5637.
28. Schubert R., Fischer R., Hain R., Schreier P.H., Bahnweg G., Ernst D., Sandermann H. Jr. An ozone-responsive region of the grapevine resveratrol synthase promoter differs from the basal pathogen-responsive sequence. Plant Mol. Biol. 34:1997;417-426.
29. Smith C.C., Peng T., Kulka M., Aurelian L. The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate early gene expression and virus growth. J. Virol. 72:1998;9131-9141.
30. Soleas G.J., Diamandis E.P., Goldberg D.M. Resveratrol: a molecule whose time has come? and gone? Clin. Biochem. 30:1997;91-113.
31. Spruance S.T., Overall J.C. Jr., Kern E.R., Krueger G.G., Pliam V., Miller W. The natural history of recurrent herpes simplex labialis-implications for anti-viral therapy. N. Eng. J. Med. 297:1977;69-75.
32. Stevens J.G., Cook M.L. Latent herpes simplex virus in spinal ganglia. Science. 173:1971;843-845.
33. Strober, W., 1997. Trypan blue exclusion test of cell viability. In: Coligan, J.E., Kruisbeck, A.M., Margulies, D.H., Shevach, E.M., Strober, W. (Eds.), Current Protocols In Immunology, Appendix 3B. John Wiley and Sons.
34. Sun N.J., Woo S.H., Cassady J.M., Snapka R.M. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J. Nat. Prod. 61:1998;362-366.
35. Taketo M., Schroeder A.C., Mobraaten L.E. et al. FVB/N: An inbred mouse strain preferable for transgenic analyses. Proc. Natl. Acad. Sci. U.S.A. 88:1991;2065-2069.
36. Vindelov L.L., Christensen I.J., Nissen N.I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 3:1983;323-327.
37. Whitley, R.J., Gnann, J.W., 1993. The epidemiology and clinical manifestations of herpes simplex virus infections. In: Roizman, B., Whitley, R.J., Lopez, C. (Eds.), The Human Herpesviruses. Lippincott-Raven, Philadelphia, p. 69.
38. Whitley R.J., Soong S.-J., Hirsch M.S., Karchmer A.W., Dolin R., Glasso G., Dunnick J.K., Alford C.A. Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N. Eng. J. Med. 304:1981;313-318.
39. Zimmerman D.H., Mundon F.K., Croson S.E., Henchal L.S., Docherty J.J., O'Neill S.P. Identification and typing of herpes simplex virus types 1 and 2 by monoclonal antibodies, sensitivity to the drug (E)-5-(2 bromovinyl)-2′-deoxyuridine, and restriction endonuclease analysis of viral DNA. J. Med. Virol. 15:1985;215-222.